Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in Decompensated Liver Cirrhosis
NCT02190357Phase 4Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Aug 2014
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifaximin in Liver cirrhosis (LC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: number of death at 6 months. Status: unknown.
02
Drugs
rifaximin
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT02190357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02190357.